"id","versionIdentifier","uuid:ID","rationale","instanceType"
"StudyVersion_1","2","13dff4dd-83f0-40f8-b038-c5caaf5db97b","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion"
